Anifrolumab

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date

May 7, 2019

https://www.dovepress.com/spotlight-on-anifrolumab-and-its-potential-for-the-treatment-of-modera-peer-reviewed-article-DDDT

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date

April 4, 2019

https://www.dovepress.com/spotlight-on-anifrolumab-and-its-potential-for-the-treatment-of-modera-peer-reviewed-article-DDDT

February 15, 2019

https://clinicaltrials.gov/ct2/show/NCT02794285?type=Intr&cond=Lupus&phase=012345&lupd_s=02%2F01%2F2019&lupd_d=14

Condition : Active Systemic Lupus Erythematosus

Interventions : Biological: Anifrolumab; Drug: Placebo

Sponsors : AstraZeneca; PRA Health Sciences

Active, not recruiting

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02794285

Thu, 09 Jun 2016 12:00:00 EDT